A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of BBI608 plus Weekly Paclitaxel vs. Placebo plus Weekly Paclitaxel in Adult Patients with Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Napabucasin (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms BRIGHTER
- Sponsors Boston Biomedical; Sumitomo Dainippon Pharma
- 05 Oct 2017 Status changed from active, no longer recruiting to discontinued.
- 23 Aug 2017 This trial has been Discontinued in Bulgaria and Germany according to European Clinical Trials Database record.
- 17 Aug 2017 This trial has been Discontinued in Estonia according to European Clinical Trials Database record.